Feb 10 () - Quest Diagnostics on Tuesday forecast 2026 profit and revenue above Wall Street estimates after beating ...
Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced that the ...
Quest Diagnostics Incorporated (NYSE:DGX) Q4 2025 Earnings Call Transcript February 10, 2026 Quest Diagnostics Incorporated ...
Jim Davis, Quest Diagnostics CEO, discusses how chronic disease management and consumer health testing are driving growth in ...
Analysts estimate that Quest Diagnostics will report an earnings per share (EPS) of $2.35. Anticipation surrounds Quest ...
Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations. | Quest ...
Quest Diagnostics (DGX) stock hits a 52-week high as the company beats estimates with its Q4 2025 financials and set its 2026 ...
Quest Diagnostics recently unveiled a suite of advanced diagnostics and support services designed to broaden access to lab tests for transplants. Quest hopes to improve testing compliance among ...
Zacks Investment Research on MSN
Quest Diagnostics Incorporated (DGX) hit a 52 week high, can the run continue?
Have you been paying attention to shares of Quest Diagnostics (DGX)? Shares have been on the move with the stock up 14.1% over the past month. The stock hit a new 52-week high of $207.05 in the ...
Quest Diagnostics completed its acquisition of select assets from Fresenius Medical Care’s laboratory business. As part of the transaction, the Secaucus-based testing provider will now offer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results